Drugs / NK-92/5.28.z
NK-92/5.28.z
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03383978 | Dec 2017 → Dec 2027 expected | glioblastoma | Johann Wolfgang Goethe University Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT00990717 | Mar 2005 → Jul 2012 | Hodgkins lymphoma, leukemia, plasma cell myeloma | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02727803 | May 2016 → May 2027 expected | B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2), Hodgkins lymphoma, acute biphenotypic leukemia, acute myeloid leukemia with multilineage dysplasia +7 | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NK-92/5.28.z | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03383978 ↗ |
| Known as | NK-92 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02727803 ↗ |
| Known as | NK-92 cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00990717 ↗ |
| Action | Deplete | “Natural killer cells may kill tumor cells” NCT02727803 ↗ |
| Modality | Cell therapy | “The infusion of an irradiated NK cell line is appealing as it is a source of cells that can be expanded to therapeutic quantities” NCT00990717 ↗ |
| Route | Intravenous | “Cells are administered as an intravenous infusion over one hour” NCT00990717 ↗ |